📊 ZBIO Key Takeaways
Is Zenas BioPharma, Inc. (ZBIO) a Good Investment?
Zenas BioPharma exhibits strong balance sheet fundamentals with $500.2M cash reserves and low debt (0.23x D/E), but severe operating losses (-$77.3M), deteriorating net income trends (-140.6% YoY), and substantial annual cash burn (-$75.2M) with flat revenue ($10M) indicate a pre-commercial biotech company with no visible near-term profitability.
Zenas BioPharma, Inc. Key Strengths (ZBIO)
- Strong cash position of $500.2M provides 6-7 years operational runway at current burn rate
- Exceptional liquidity with 11.94x current and quick ratios providing financial flexibility
- Low leverage with 0.23x debt-to-equity ratio and minimal debt burden of $78.6M
ZBIO Stock Risks: Zenas BioPharma, Inc. Investment Risks
- Severe and deteriorating profitability with -$77.3M operating income and net income declining 140.6% YoY
- Substantial annual cash burn of $75.2M with minimal revenue generation, unsustainable without external funding beyond 6-7 years
- Pre-commercial biotech model with zero revenue growth (0% YoY) and no demonstrated path to profitability; subject to typical biotech execution risks
Key Metrics to Watch
- Operating cash burn rate and depletion of cash reserves
- Revenue inflection point and growth trajectory toward sustainability
- Operating margin trend and progress toward breakeven profitability
Zenas BioPharma, Inc. (ZBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.94x current ratio provides a solid financial cushion.
ZBIO Profit Margin, ROE & Profitability Analysis
ZBIO vs Healthcare Sector: How Zenas BioPharma, Inc. Compares
How Zenas BioPharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zenas BioPharma, Inc. Stock Overvalued? ZBIO Valuation Analysis 2026
Based on fundamental analysis, Zenas BioPharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zenas BioPharma, Inc. Balance Sheet: ZBIO Debt, Cash & Liquidity
ZBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zenas BioPharma, Inc.'s revenue has declined by 80% over the 5-year period, indicating business contraction. The most recent EPS of $-11.89 indicates the company is currently unprofitable.
ZBIO Revenue Growth, EPS Growth & YoY Performance
ZBIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.0M | -$33.6M | $-0.80 |
| Q3 2025 | $10.0M | -$27.8M | $-1.22 |
| Q2 2025 | $10.0M | -$27.8M | $-1.25 |
| Q1 2025 | $10.0M | -$27.8M | $-0.80 |
| Q3 2024 | $50.0M | -$12.5M | $1.96 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zenas BioPharma, Inc. Dividends, Buybacks & Capital Allocation
ZBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zenas BioPharma, Inc. (CIK: 0001953926)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZBIO
What is the AI rating for ZBIO?
Zenas BioPharma, Inc. (ZBIO) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZBIO's key strengths?
Claude: Strong cash position of $500.2M provides 6-7 years operational runway at current burn rate. Exceptional liquidity with 11.94x current and quick ratios providing financial flexibility.
What are the risks of investing in ZBIO?
Claude: Severe and deteriorating profitability with -$77.3M operating income and net income declining 140.6% YoY. Substantial annual cash burn of $75.2M with minimal revenue generation, unsustainable without external funding beyond 6-7 years.
What is ZBIO's revenue and growth?
Zenas BioPharma, Inc. reported revenue of $10.0M.
Does ZBIO pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
Where can I find ZBIO SEC filings?
Official SEC filings for Zenas BioPharma, Inc. (CIK: 0001953926) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZBIO's EPS?
Zenas BioPharma, Inc. has a diluted EPS of $-1.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ZBIO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Zenas BioPharma, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ZBIO stock overvalued or undervalued?
Valuation metrics for ZBIO: ROE of -24.1% (sector avg: 15%), net margin of -809.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ZBIO's AI grade for 2026?
Our dual AI analysis gives Zenas BioPharma, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZBIO's free cash flow?
Zenas BioPharma, Inc.'s operating cash flow is $-75.2M, with capital expenditures of $2.0K. FCF margin is -752.0%.
How does ZBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -809.9% (avg: 12%), ROE -24.1% (avg: 15%), current ratio 11.94 (avg: 2).